You et al., 2023 found that KEAP1 and p-AIFM are highly expressed in psoriasis lesions. Simultaneously, the knockdown of KEAP1 can induce oxeiptosis. Additionally, 4-octylitaconate, an agonist of oxeiptosis, helps alleviate psoriasis by inhibiting KEAP1 (You et al., 2023). Here, KEAP1 is linked to psoriasis.